Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients [6]

Transplantation

Volumn 76, Issue 2, 2003, Pages 441-442

  Sureshkumar, Kalathil K ^a   Nghiem, Dai D ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; AGED; AGING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LETTER; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STEROID THERAPY; SURVIVAL RATE;

AGED; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 0042991509     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000074313.67552.46     Document Type: Letter

References (4)

1. Johnson DW, Nicol DL, Purdie DM, et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation 2002; 73: 1158-1163.
2. Nghiem DD, Gignac MR, Marcus R, et al. Mycophenolate mofetil reduces late allograft loss: a 4-year study. Transplantation Proc 2002; 34: 1683.
3. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
4. Ojo AO, Meier-Kriesche H-U, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409.